Volrustomig
- Generic Name
- Volrustomig
A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT06943833
- Locations
- 🇷🇺
Research Site, Yekaterinburg, Russian Federation
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06792695
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Phase 2
Recruiting
- Conditions
- Cervical CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT06535607
- Locations
- 🇨🇳
Research Site, Wuhan, China
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06448754
- Locations
- 🇮🇹
Research Site, Verona, Italy
🇨🇳Research Site, Taipei, Taiwan
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
Early Phase 1
Recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Biological: RilvegostomigBiological: SabestomigCombination Product: AZD9592 + RilvegostomigCombination Product: AZD9592 + VolrustomigCombination Product: AZD9592 + SabestomigCombination Product: AZD9592 + Pembrolizumab
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Presage Biosciences
- Target Recruit Count
- 15
- Registration Number
- NCT06366451
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸UC Davis, Sacramento, California, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Phase 3
Recruiting
- Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1145
- Registration Number
- NCT06129864
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Phase 3
Recruiting
- Conditions
- Unresectable Pleural Mesothelioma
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT06097728
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Phase 3
Recruiting
- Conditions
- Locally Advanced Cervical Cancer
- Interventions
- Other: Placebo
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT06079671
- Locations
- 🇹🇷
Research Site, Karsiyaka, Turkey
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
Phase 3
Recruiting
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT05984277
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 102
- Registration Number
- NCT05888857
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath